Outside of surgery, physicians can do very little to treat severe rotator cuff tears. Israeli company OrthoSpace is aiming to offer a new treatment option. It's raised an $8 million venture round led by Healthpoint Capital that will finance a pivotal, U.S. trial for the company's biodegradable balloon system InSpace.
An MIT team is developing implants that can withstand attacks from the body's immune system, which generally treats foreign objects as invaders.
Mitral valve replacement is intended to be the next big thing at Edwards Lifesciences, though it's still in the early research stage. But, for now, the company has paused a clinical trial due to safety concerns. Specifically, the company said it has "observed evidence of valve thrombosis" in a clinical trial of its Fortis transcatheter mitral valve replacement device.
Micro eye stent developer Glaukos has filed to raise up to $86 million in an IPO to advance an already marketed product, as well as to further develop three additional ones in its pipeline. In the last few years, Glaukos has significantly grown revenues but has held its net losses steady, suggesting that it could be on a path to achieving profitability.
Redwood City, CA-based Autonomic Technologies has brought in two new European investors and committed to a German subsidiary as part of a $38 million Series D round. The financing will go to back European marketing and a U.S. pivotal trial for its headache microstimulator Pulsante.
The world's smallest cardiac monitor implant is on track to make a move into the doctor's office. Medtronic's aim is to further capitalize upon a hugely successful launch of its Reveal Linq that's already exceeded all expectations with a potential for drug-like blockbuster annual sales of $1 billion to $2 billion.
A second patient using Carmat's artificial heart died over the weekend. Trading of the French company on the Euronext stock exchange was suspended.
As the med tech industry targets innovative technologies to treat orthopedic injuries, scientists are developing artificial knee implants that could help ward off arthritis and surgery further down the road.
Under investigation by the FDA following claims of dangerous side effects and fraudulent clinical trial data, Bayer has released new data from a long-term study the German drugmaker says supports the safety and effectiveness of its Essure contraceptive inserts.
The FDA has approved the Protégé MRI spinal cord stimulation system to treat chronic pain, along with the related MRI compatible leads, from St. Jude Medical. The device also offers the benefit of enabling future updates via wireless software upgrades rather than requiring its replacement to gain the benefits of new developments.